Dashboard
Manage Tickers

NUVL


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nuvalent-to-present-patient-reported-outcomes-data-from-the-phase-2-portion-of-the-arros-1-phase-12-clinical-trial-of-zidesamtinib-and-encore-pivotal-efficacy-and-safety-data-from-the-arros-1-trial-at-2025-iaslc-asco-north-america-conference-on-lung-cancer
Nuvalent To Present Patient-Reported Outco...
11/04/2025 22:17:01

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for c...

ubs-maintains-buy-on-nuvalent-raises-price-target-to-132
UBS Maintains Buy on Nuvalent, Raises Pric...
10/31/2025 15:56:30

UBS analyst David Dai maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $114 to $132.

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

nuvalent-q3-eps-170-misses-136-estimate
Nuvalent Q3 EPS $(1.70) Misses $(1.36) Est...
10/30/2025 10:38:46

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(1.70) per share which missed the analyst consensus estimate of $(1.36) by...

piper-sandler-maintains-overweight-on-nuvalent-raises-price-target-to-128
Piper Sandler Maintains Overweight on Nuva...
10/27/2025 13:13:20

Piper Sandler analyst Kelsey Goodwin maintains Nuvalent (NASDAQ:NUVL) with a Overweight and raises the price target from $11...

reported-saturday-nuvalents-neladalkib-shows-44-response-rate-across-14-advanced-alk-positive-solid-tumors-beyond-nsclc-phase-2-alkove-1-trial-enrollment-ongoing-globally
Reported Saturday, Nuvalent's Neladalkib S...
10/20/2025 08:14:08

Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumorsGlobal enrollment ongoing for...

stifel-reinstates-buy-on-nuvalent-announces-115-price-target
Stifel Reinstates Buy on Nuvalent, Announc...
10/16/2025 13:54:38

Stifel analyst Laura Prendergast reinstates Nuvalent (NASDAQ:NUVL) with a Buy and announces $115 price target.

cantor-fitzgerald-initiates-coverage-on-nuvalent-with-overweight-rating-announces-price-target-of-135
Cantor Fitzgerald Initiates Coverage On Nu...
10/15/2025 14:09:15

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Nuvalent (NASDAQ:NUVL) with a Overweight rating and announces ...

nuvalent-to-present-preclinical-intracranial-activity-of-her2-selective-inhibitor-nvl-330-at-aacr-nci-eortc-international-conference-2025
Nuvalent To Present Preclinical Intracrani...
10/13/2025 16:55:40

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for c...

wedbush-reiterates-outperform-on-nuvalent-maintains-115-price-target
Wedbush Reiterates Outperform on Nuvalent,...
09/08/2025 13:10:59

Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $115 price target.

nuvalent-presented-pivotal-data-for-zidesamtinib-in-tki-pretreated-patients-with-advanced-ros1-positive-non-small-cell-lung-cancer-from-its-global-arros-1-phase-12-trial-on-track-to-complete-its-rolling-nda-submission-in-q3-2025
Nuvalent Presented Pivotal Data For Zidesa...
09/07/2025 16:18:25

The pivotal data presented today, initially announced in June 2025, serve as the foundation for the company's ongoing rolli...

guggenheim-assumes-nuvalent-at-buy-announces-price-target-of-122
Guggenheim Assumes Nuvalent at Buy, Announ...
09/04/2025 14:07:56

Guggenheim analyst Brad Canino assumes Nuvalent (NASDAQ:NUVL) with a Buy rating and announces Price Target of $122.

raymond-james-initiates-coverage-on-nuvalent-with-outperform-rating-announces-price-target-of-105
Raymond James Initiates Coverage On Nuvale...
09/03/2025 16:51:18

Raymond James analyst Chris Raymond initiates coverage on Nuvalent (NASDAQ:NUVL) with a Outperform rating and announces Pric...

this-thermo-fisher-scientific-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday
This Thermo Fisher Scientific Analyst Begi...
08/19/2025 13:43:31

piper-sandler-initiates-coverage-on-nuvalent-with-overweight-rating-announces-price-target-of-112
Piper Sandler Initiates Coverage On Nuvale...
08/19/2025 11:50:06

Piper Sandler analyst Kelsey Goodwin initiates coverage on Nuvalent (NASDAQ:NUVL) with a Overweight rating and announces Pri...

nuvalent-to-present-pivotal-data-for-zidesamtinib-in-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc-from-global-arros-1-phase-12-clinical-trial-in-addition-to-preliminary-data-for-tki-nave-patients-at-wclc-2025
Nuvalent To Present Pivotal Data For Zides...
08/13/2025 17:10:16

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for c...

nuvalent-says-cash-and-equivalents-and-marketable-securities-were-1b-as-of-june-30-company-continues-to-believe-its-existing-cash-and-marketable-securities-will-be-sufficient-to-fund-its-current-operating-plan-into-2028
Nuvalent Says Cash And Equivalents And Mar...
08/07/2025 10:41:35

nuvalent-q2-eps-139-misses-122-estimate
Nuvalent Q2 EPS $(1.39) Misses $(1.22) Est...
08/07/2025 10:40:12

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.22) by...

nuvalent-announces-first-patient-dosed-in-alkazar-phase-3-randomized-controlled-trial-evaluating-neladalkib-for-tki-nave-patients-with-advanced-alk-positive-nsclc-versus-alecensa
Nuvalent Announces First Patient Dosed In ...
07/21/2025 10:32:08

baird-maintains-outperform-on-nuvalent-raises-price-target-to-112
Baird Maintains Outperform on Nuvalent, Ra...
06/25/2025 13:15:13

Baird analyst Colleen Kusy maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $105 to $112.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION